###### Strengths and limitations of this study

Many Western nations position general practitioners (GPs) as the gatekeeper to specialist services, while enabling their access to diagnostic tests. This can be particularly helpful in cancer care.GPs were invited to review video-vignettes of patients with possible cancer symptoms and decide how they would manage these patients.There was limited evidence that appropriate tests would be ordered, and a significant proportion of high-risk cases were not immediately referred for further investigation or specialist opinion.The study design did not examine the reasons for the GP decisions.Some patients may receive a delayed cancer diagnosis, even when they present with typical cancer symptoms to a GP who can access relevant diagnostic tests.

Introduction {#s1}
============

Australians who experience symptoms do not have direct access to specialists, but are required to consult a general practitioner (GP) or attend an emergency department.[@R1] Akin to other health systems,[@R2] the Australian health system positions GPs as the gatekeeper to specialist services.[@R3]

In Australia, GPs can refer for a range of tests including ultrasounds and CT scans and, with specific indications, some MRI. In some Australian jurisdictions, GPs can also directly refer for gastroscopy and colonoscopy. This represents a greater range of tests relative to other health systems, like in the UK.[@R4]

GP access to diagnostic tests is particularly helpful in cancer care.[@R5] It can optimise the timely receipt of appropriate treatment and as such reduce, if not avert, the personal, social and economic costs of cancer.[@R6] Given the complexity of health systems, it can be difficult (if not impossible) to isolate definitive causal relationships between GP diagnostic tests and cancer outcomes.[@R9] [@R10] However, GP access to diagnostic tests is likely to help identify those patients who require urgent care.[@R11]

As part of a larger pre--post, randomised control trial of an interactive online referral pro forma*,*[@R12] the review of data reported here focused on how Australian GPs manage patients with cancer symptoms. The intervention tested in the original trial did not aim to guide GP referral, investigation or prescribing practices---as such, its focus is not germane to the focus of this review, which encompasses data from both phases.[@R12]

Methods {#s2}
=======

Following clearance from the relevant ethics committee, the research team recruited GPs in seven Australian states and territories to participate in this study via email, newsletters and personal contact. Recruitment was facilitated by primary care networks, university departments, research networks and personal contacts. GPs were eligible to participate if they were currently in practice, including registrars (or vocational trainees), and had internet access. As such, the exact number of GPs who were aware of the project cannot be ascertained.

Participants were invited to consider the symptoms of patients presented as video-vignettes and to determine how they would manage the patient. This was conducted in two phases---before the participants were provided with an interactive referral pro forma, and afterwards. The pro forma aimed to improve the quantity and quality of patient information communicated between primary and secondary care clinicians. The focus of this paper, however, is to determine how GPs respond to patients with different cancer symptoms, regardless of whether this was before or after using the pro forma.

Guided by the 2005 referral guidelines for suspected cancer of the National Institute for Health and Clinical Excellence (NICE),[@R13] 24 video-vignettes were developed by six GPs, four videos for each of six cancer types ([table 1](#BMJOPEN2015008525TB1){ref-type="table"}). These guidelines were selected as they indicate the need for specialist referral based on specific high-risk presentations; furthermore, at the time of the study, no equivalent Australia-wide guidelines were available for all cancer types. The video-vignettes comprised a 4 min video monologue delivered by an actor--patient accompanied by case notes containing the patient\'s medical history, current medication, allergies and previous consultations. The video included an off-camera commentary by an actor--doctor describing clinical signs to be found at this visit.

###### 

Cancer cases

  Cancer type   Case details
  ------------- -----------------------------------------------------------------------------------------------------------------------------------
  Bladder       76-year-old woman with asymptomatic frank haematuria
  Breast        35-year-old with asymptomatic, firm breast lump and skin dimpling
  Breast        69-year-old with skin changes consistent with Paget\'s disease of the breast
  Cervical      34-year-old with CIN 2
  Colorectal    60-year-old with unexplained iron deficiency anaemia, abdominal pain and right iliac fossa abdominal mass
  Endometrial   65-year-old with PMB
  Lung          58-year-old lifelong smoker with haemoptysis, breathlessness and weight loss
  Oesophageal   66-year-old with 10 kg weight loss and dysphagia for solids
  Pancreatic    57-year-old with 5 kg weight loss, jaundice, generalised pruritus and pancreatic mass on abdominal ultrasound scan
  Prostate      55-year-old with a PSA of 22, urinary frequency, haematuria, hesitancy and terminal dribbling
  Lung          49-year-old smoker with cervical lymphadenopathy, haemoptysis and a 2 cm mass on chest X-ray
  Colorectal    65-year-old with rectal bleeding, diarrhoea, fatigue and rectal mass
  Bladder       65-year-old man with frank asymptomatic haematuria
  Breast        38-year-old with a 3-month history of breast lump, dimpling of skin and axillary lymphadenopathy
  Breast        71-year-old with a breast lump and *peau d\'orange*
  Cervical      36-year-old with CIN 2 and postcoital bleeding
  Colorectal    62-year-old man with a 2-month history of constipation, abdominal pain, hepatomegaly and iron deficiency anaemia
  Endometrial   62-year-old with several episodes of PMB
  Lung          60-year-old woman with cough, dyspnoea, weight loss, hoarseness, pleural effusion and clubbing
  Lung          61-year-old man with cough, suspicious lesion on chest X-ray and haemoptysis
  Oesophageal   69-year-old man with dysphagia for solids, weight loss, dyspepsia and fatigue
  Pancreatic    60-year-old man with abdominal pain, chronic pancreatitis, weight loss, jaundice and pancreatic mass on abdominal ultrasound scan
  Prostate      70-year-old abnormal digital rectal examination findings, PSA of 25, chronic retention, prostatism and low back pain
  Colorectal    63-year-old woman with altered bowel habits, iron deficiency anaemia, abdominal pain, weight loss and rectal bleeding

CIN, cervical intraepithelial neoplasia; PMB, postmenopausal bleeding; PSA, prostate-specific antigen.

After accessing a secured research website, participants: provided demographic information; received the case notes of each patient; viewed the video-vignette of the consultation once and received examination findings. Participants then chose to: (1) prescribe medication; (2) order diagnostic tests and/or (3) refer the patient to a specialist. Participants documented the prescription, the test, and/or the referral as they would when consulting a *bona fide* patient. Each participant viewed and managed 24 video-vignettes.

Participants were recompensed for their participation and could claim continuing medical education points. Progress through the video-vignettes could be tracked online and reminders were issued to those who had not completed the study after 2 weeks of inactivity.

Statistical analysis {#s2a}
--------------------

Descriptive statistics (number and percentage) were used to report participants' management of each scenario, preintervention and postintervention. A multinominal logistic model was used to assess the influence of demographic information and specialty on the ways the participants chose to manage the patient, with particular reference to: 'prescription only', 'investigation(s) only', 'referral only' and 'referral with investigation(s)'. 'Investigation only' was selected as the base outcome, and the relative risk ratio of 'prescription only', 'referral only' and 'referral and investigation' are reported. User-defined parsimonious models were constructed in a backward elimination fashion from the full model. The full model included: (1) participants' demographic data---notably age, gender, country of graduation, number of years since graduation, years of GP experience, Fellowship of the Royal Australian college of General Practitioners (FRACGP), clinic remoteness (4 categories: major cities, inner regional, outer regional and remote/very remote), role within their primary practice, patients consulted per week (3 categories: \<100, 100--149, ≥150), direct patient care hours per week (4 categories: \<11, 11--20, 21--40, ≥41), non-English consultation (no and yes), number of GPs within their primary practice, and number of patient sessions per week and (2) cancer type. Only variables with p\<0.05 were retained in the final model. The categories of some variables were regrouped as noted, before they were entered into the model, due to their small number. In the regression, preintervention and postintervention data were pooled according to cancer types. Given the lack of independence between participant responses, regression models were adjusted by estimating the cluster effect using the 'vce' option within Stata. p Values of \<0.05 were considered statistically significant. Stata MP 13.1 (StataCorp, Texas, USA) was used to perform the analysis.

Results {#s3}
=======

Between August 2011 and August 2012 (inclusive), 102 GPs were recruited. Participants were mainly from Western Australia (46%) and Victoria (25%), with a mean age of 43 years ([table 2](#BMJOPEN2015008525TB2){ref-type="table"}). On average, the participants had 13 years of GP experience; however, 24% were trainees. Most participants primarily practised in a capital city or another metropolitan area.

###### 

Participant demographics (n=102)

                                         Participants   National comparison   
  -------------------------------------- -------------- --------------------- --------------
  Age, years                             43             11.8                  50.5\*
  Years after graduation                 19             11.3                  
  Years as GP                            13             11.1                  
  GPs in primary practice                8              4.1                   
  GP sessions/week                       6              3.0                   
                                                                              
                                         **N°**         **%**                 
                                                                              
  Male                                   58             56.9                  60.9%†[@R17]
  Graduated in Australia                 73             71.6                  65.9%†
  GP registrar                           24             23.5                  3.8%‡
  FRACGP                                 58             56.9                  56.8¶
  Accredited practice                    101            99.0                  88.6¶
  Position                                                                    
   Principal                             21             20.6                  
   Non-principal                         63             61.8                  
   Other                                 18             17.6                  
  State                                                                       
   New South Wales                       13             12.7                  33.1%‡
   Queensland                            7              6.8                   19.5%‡
   Victoria                              25             24.5                  25.1%‡
   South Australia                       7              6.9                   8.4%‡
   Tasmania                              1              1.0                   2.6%‡
   Western Australia                     47             46.1                  9.1%‡
   Australian Capital Territory          2              2.0                   1.5%‡
  Region of primary practice                                                  
   Capital city                          49             48.0                  66.3%¶
   Other metropolitan area               38             37.3                  7.6%¶
   Large rural area                      5              4.9                   6.7%¶
   Small rural area                      6              5.9                   7.1%¶
   Other rural area                      3              2.9                   10.6%¶
   Remote centre                         1              1.0                   0.6%¶
  Remoteness of the region                                                    
   Major city                            73             71.6                  71.5%‡
   Inner regional area                   15             14.7                  18.9%‡
   Outer regional area                   10             9.8                   7.8%‡
   Remote area                           3              2.9                   1.2%‡
   Very remote area                      1              1.0                   0.6%‡
  Patients consulted, per week                                                
   \<100                                 49             48.0                  
   100--149                              30             29.4                  
   150--199                              20             19.6                  
   \>199                                 3              3.0                   
  Direct patient care, h/week                                                 
   \<11                                  11             10.8                  1.2%¶
   11--20                                21             20.6                  12.2%¶
   21--40                                47             46.1                  53%¶
   41--60                                20             19.6                  32.1%¶
   \>60                                  3              2.9                   1.4%¶
  Non-English patient consultations, %                                        
   0                                     84             82.3                  72.6%¶
   \<25                                  17             16.7                  21.7%¶
   25--50                                0              0                     2.9%¶
   \>50                                  1              1.0                   2.8%¶

\*Sourced from Britt *et al*[@R14] and the Australian Institute of Health and Welfare.[@R15]

†Sourced from Britt *et al*.[@R14]

‡Sourced from General Practice Education and Training Limited.[@R16]

§Sourced from the Primary Health Care Research & Information Service.[@R17]

¶Compared to GPs involved in Britt *et al*.[@R14]

FRACGP, Fellowship of the Royal Australian college of General Practitioners; GP, general practitioners.

Patient management varied by cancer case. Before the intervention, relatively few participants managed the patient with a 'prescription only' (range=1.0--10.8%, mean=2.8%, [table 3](#BMJOPEN2015008525TB3){ref-type="table"}). After the intervention, more chose to manage the patient with a 'prescription' (9.8--32.6%, mean=21.5%) or an 'investigation only' (range=25.0--71.7%, mean=43.5%). Of all the demographic data pertaining to the doctors, the only factor that appeared to influence their decisions was the geographical location of their practice (p\<0.001 of the overall Wald test after regression).

###### 

GP management decisions\*

  Cancer                      Prescription only   Investigation(s) only   Referral only   Referred with investigation(s)                      
  --------------------------- ------------------- ----------------------- --------------- -------------------------------- ----- ------ ----- ------
  *Preintervention (n=102)*                                                                                                                   
  Bladder                     1                   1.0                     58              56.9                             16    15.7   27    26.5
  Breast                      3                   2.9                     71              69.6                             15    14.7   13    12.7
  Breast                      11                  10.8                    53              52.0                             16    15.7   22    21.6
  Cervical                    4                   3.9                     3               2.9                              72    70.6   23    22.5
  Colorectal                  2                   2.0                     19              18.6                             66    64.7   15    14.7
  Endometrial                 3                   2.9                     39              38.2                             33    32.4   27    26.5
  Lung                        1                   1.0                     58              56.9                             12    11.8   31    30.4
  Oesophageal                 1                   1.0                     23              22.5                             49    48.0   29    28.4
  Pancreatic                  2                   2.0                     11              10.8                             55    53.9   34    33.3
  Prostate                    1                   1.0                     13              12.7                             65    63.7   23    22.5
  Total                       29                  2.8                     348             34.1                             399   39.1   244   23.9
  *Postintervention (n=92)*                                                                                                                   
  Lung                        25                  27.2                    38              41.3                             18    19.6   11    12.0
  Colorectal                  35                  38.0                    20              21.7                             30    32.6   7     7.6
  Bladder                     15                  16.3                    54              58.7                             9     9.8    14    15.2
  Breast                      13                  14.1                    56              60.9                             8     8.7    15    16.3
  Breast                      14                  15.2                    57              62.0                             9     9.8    12    13.0
  Cervical                    20                  21.7                    33              35.9                             19    20.7   20    21.7
  Colorectal                  21                  22.8                    34              37.0                             21    22.8   16    17.4
  Endometrial                 15                  16.3                    46              50.0                             12    13.0   19    20.7
  Lung                        9                   9.8                     66              71.7                             5     5.4    12    13.0
  Lung                        18                  19.6                    42              45.7                             15    16.3   17    18.5
  Oesophageal                 26                  28.3                    29              31.5                             18    19.6   19    20.7
  Pancreatic                  30                  32.6                    23              25.0                             29    31.5   10    10.9
  Prostate                    14                  15.2                    36              39.1                             16    17.4   26    28.3
  Colorectal                  22                  23.9                    26              28.3                             22    23.9   22    23.9
  Total                       277                 21.5                    560             43.5                             231   17.9   220   17.1

\*Percentages may not total 100% due to rounding.

Patient management also varied significantly by cancer type (p\<0.001 of the overall Wald test, [table 4](#BMJOPEN2015008525TB4){ref-type="table"}). Colorectal cancer symptoms were managed almost equally across the choice of options with a similar proportion managed with each of the three options. Compared to the management of colorectal cancer symptoms, participants were less likely to manage breast, bladder, endometrial and lung cancer symptoms with a 'prescription' or 'referral only'. They were less likely to manage prostate cancer with a 'prescription only', yet more likely to manage it with a 'referral with investigation'. With regard to pancreatic and cervical cancers, participants were more likely to manage these with a 'referral only' or a 'referral with investigation', relative to the management of colorectal cancer. Compared with those who practised in a major city, participants who practised in a remote or very remote practice were significantly less likely to opt for a 'prescription' or a 'referral only', yet more likely to manage the patient with an 'investigation only' (see [table 4](#BMJOPEN2015008525TB4){ref-type="table"}). The investigations and treatment options suggested are presented in [table 5](#BMJOPEN2015008525TB5){ref-type="table"}.

###### 

Factors associated with GP cancer management (n=2308)

  Video                                   rrr (95% CI)   rrr (95% CI)           rrr (95% CI)                                 
  --------------------------------------- -------------- ---------------------- -------------- ---------------------- ------ ----------------------
  Cancer (colorectal, rrr=1)                                                                                                 
   Breast                                 0.21           (0.14 to 0.32)\*\*\*   0.14           (0.09 to 0.22)\*\*\*   0.42   (0.28 to 0.65)\*\*\*
   Bladder                                0.17           (0.10 to 0.30)\*\*\*   0.16           (0.09 to 0.27)\*\*\*   0.60   (0.37 to 0.95)\*
   Endometrial                            0.26           (0.15 to 0.46)\*\*\*   0.37           (0.23 to 0.60)\*\*\*   0.88   (0.57 to 1.36)
   Prostate                               0.38           (0.20 to 0.73)\*\*     1.18           (0.82 to 1.71)         1.65   (1.05 to 2.60)\*
   Pancreatic                             1.17           (0.68 to 2.02)         1.78           (1.10 to 2.86)\*       2.15   (1.30 to 3.56)\*\*
   Cervical                               0.83           (0.51 to 1.36)         1.82           (1.30 to 2.54)\*\*\*   1.98   (1.30 to 3.02)\*\*\*
   Lung                                   0.32           (0.21 to 0.46)\*\*\*   0.17           (0.11 to 0.26)\*\*\*   0.57   (0.39 to 0.83)\*\*
   Oesophageal                            0.64           (0.42 to 0.99)\*       0.92           (0.63 to 1.34)         1.52   (1.01 to 2.29)\*
  Clinic remoteness (major city, rrr=1)                                                                                      
   Inner regional                         0.84           (0.44 to 1.62)         0.46           (0.29 to 0.73)\*\*\*   0.82   (0.38 to 1.75)
   Outer regional                         0.57           (0.17 to 1.95)         1.13           (0.50 to 2.51)         1.15   (0.50 to 2.64)
   Remote/very remote                     0.05           (0.01 to 0.25)\*\*\*   0.42           (0.26 to 0.67)\*\*\*   0.41   (0.09 to 1.83)

Results are rrr for the participant groups whose management was 'prescription only', 'referral only' or 'referral with investigation' compared to those who selected 'investigations only' (rrr=1). Results were derived from one multinomial logistic regression with the adjustment of clustering effect due to assessment of different cancers made by the same participant.

\*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001.

rrr, relative risk ratio.

###### 

Investigations requested and prescriptions per cancer type

  Cancer type   Investigations                                                                                                                                                                                                                                                                                                              Prescriptions ordered
  ------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------
  Breast        Mammogram, fine-needle biopsy, full blood count, renal function test, liver function test, ultrasound scan                                                                                                                                                                                                                  Antifungals, antibiotic tablets or creams, steroid creams, antihistamines
  Lung          CT scan/chest X-ray, ultrasound scan, fine-needle aspiration, bronchoscopy, spirometry, lung biopsy, full blood count, renal function test, liver function test, coagulation studies, ferritin, sputum microscopy and culture/cytology, Mantoux test                                                                        Steroid tablets, antibiotics, diuretics, codeine, steroid inhalers, β-agonist inhalers
  Prostate      Urine microscopy and culture, urine cytology, PSA, CT, ultrasound scan, full blood count, renal function, liver function test, X-ray                                                                                                                                                                                        Opiates, paracetamol, non-steroidal anti-inflammatory tablets, α-blockers, 5α-reductase enzyme inhibitors
  Bladder       Urine microscopy and culture, urine cytology, PSA, CT, ultrasound scan, full blood count, renal function, liver function test, intravenous pyelogram                                                                                                                                                                        Nil
  Colorectal    Colonoscopy/gastroscopy, CT/ultrasound scan, stool culture and sensitivity, cytology, faecal occult blood test, full blood count, renal function test, liver function test, erythrocyte sedimentation rate, iron studies, lipase, calcium, magnesium, phosphate                                                             Paracetamol, iron supplements, iron injections, laxatives, antispasmodics, vitamin C, opiates
  Pancreatic    Full blood count, renal function test, liver function test, blood glucose, coagulation profile, amylase, lipase, bilirubin, CT, ultrasound scan/bone scan                                                                                                                                                                   Paracetamol, codeine, opiates, cholestyramine, vitamin B~12~, proton-pump inhibitors
  Oesophageal   Barium swallow/chest X-ray, CT/ultrasound scan, gastroscopy, full blood count, renal function test, liver function test, iron studies, coagulation studies, urea breath test/*Helicobacter pylori* serology                                                                                                                 Antiemetics, food supplements, proton-pump inhibitors
  Cervical      Vaginal swab MCS/Pap smear, human papilloma virus cytology, urine culture and sensitivity, chlamydia, gonorrhoea PCR, human immune deficiency virology, hepatitis B, hepatitis C, syphilis serology, VDRL, full blood count, renal function test, liver function test, ferritin, ultrasound scan/CT, colposcopy/endoscopy   Nil
  Endometrial   US pelvic/vaginal, full blood count, renal function test, liver function test, iron studies, coagulation studies, Pap smear/swab, urine culture and sensitivity, X-ray, CT, hysteroscopy                                                                                                                                    Oestrogen replacement vaginal pessaries

MCS, mid stream urine; PSA, prostate-specific antigen; US, ultrasound; VDRL, Venereal Disease Research Laboratory.

Discussion {#s4}
==========

Findings {#s4a}
--------

According to the 2005 NICE guidelines, all cases in this study warranted a specialist review within 2 weeks.[@R13] The research results suggest that in more than one-in-eight cases, the patient was not investigated or referred, despite symptoms that were highly suggestive of cancer. In some cases, the indication for the drugs prescribed as per [table 5](#BMJOPEN2015008525TB5){ref-type="table"} was unclear and in the case of endometrial cancer, the prescription of oestrogen replacement therapy may have actually advanced cancer progression.[@R18]

Compared to cases presenting with colorectal symptoms, participants were more likely to refer a patient presenting with symptoms of pancreatic, prostate or cervical cancer, with or without further investigation. These cases included relatively more objective signs of pathology sourced from a laboratory and/or radiological report. This suggests that, despite the UK guidelines, these participants may have been reticent to refer patients without further investigation---this was particularly the case for breast, bladder, endometrial and lung cancers where the patient presented with signs and symptoms, without confirmatory laboratory tests. Notably, in the case of lung cancer, a suspicious lesion on a chest X-ray did not appear to warrant immediate referral in most cases.

The participants appeared to have different views on how to manage patients with cancer symptoms---and the reason for these opinions could not be gleaned (eg, X-ray for endometrial cancer). This might suggest that the participants collectively recognised both the advantages and disadvantages associated with further investigation. The former may include the efficient use of limited diagnostic and subsequent specialist services. This may be particularly advantageous for patients who do not reside in close proximity to specialist services. This was suggested by the study results, as participants who practised in rural and remote locations were more likely to request further investigation prior to referral; yet research suggests that cancer outcomes in these locations are worse than in metropolitan areas.[@R19] The disadvantages associated with locally conducted investigation may include the financial cost to the patient, as well as delayed specialist advice and care.[@R20]

Strengths and weaknesses of the study {#s4b}
-------------------------------------

A key strength of this study is consistency in both the cases reviewed by the participants and the way they reviewed the cases. Furthermore, participants were unaware of the case content before commencing the study. As such, participants did not simply include GPs with a particular interest in cancer care.

However, the study is limited in four key ways. First, it did not enable interaction between the participant and the patient, or the participant and the specialist. Such communication is likely to promote effective patient care. Second, data were not collected on review plans to better understand the participants' perspectives on the case. This may be particularly relevant for the option, 'investigation only', where a subsequent review may help to confirm a diagnosis and lead to referral. Third, since the participants differed from GPs who practise in Australia, the generalisability of the findings is limited. Similarly, the number of participants from very remote areas was limited to four. Finally, data were not collected on participants' reasons for their selected patient management strategy. Despite these limitations, the results from this study reveal an important need to examine how patient outcomes are affected by the ways GPs respond to patients' cancer symptoms.

Comparison with other literature {#s4c}
--------------------------------

Although the findings from this study may cause concern, the study is limited by the use of video-vignettes, which prevented participants from interacting with the patient or their families. Such interactions may increase the prospect of referral.[@R21] Research also suggests that a cancer diagnosis can be missed where there are: atypical presentations, non-specific presentations, very low prevalence rates, comorbidities and/or perceptual features.[@R22] All cases in this study were typical and devoid of distracting features. Furthermore, participants were more inclined to manage the patient with investigations or a referral when using the interactive referral pro forma. As the pro forma required detailed patient information, participants may have been prompted to request additional evidence---like that of a pathology report---before referring the patient to a specialist. The risk in this case is of false negative investigation findings. Furthermore, a recent report on delayed cancer diagnoses noted a 'lack of reporting culture in primary care compared with acute hospitals... \[As such\] any analysis will show only a small proportion of incidents in primary care, and from general practice in particular'. [@R23] This may explain the limited literature on potential delays to cancer diagnosis within primary care. The data presented here suggest a risk of delay. The review also concluded that some of the factors that contribute to practitioner delay included: symptom misattribution and/or no examination or investigation of malignancy. The data presented in this paper support these conclusions.

Implications for clinicians and policymakers {#s4d}
--------------------------------------------

Results from this study suggest that some patients may receive a delayed cancer diagnosis, even when they present with typical cancer symptoms to a GP who can access relevant diagnostic tests. There was limited evidence that appropriate tests would be ordered, and a significant proportion of cases were not immediately referred for further investigation or specialist opinion. Therefore, better cancer outcomes may not be solely explained by GP access to investigations, but rather to other factors that were beyond the scope of this study. These may include expedient access to specialists via the private healthcare sector or different systems of care.

Future directions {#s4e}
-----------------

Research is required to understand how GPs filter and use clinical information to determine the management of patients who present with cancer symptoms. Research is also required to identify efficient and effective referral pathways for these patients as they traverse the health system and progress along the care continuum.

Conclusion {#s5}
==========

Patients may receive a delayed cancer diagnosis, even when they present with typical cancer symptoms to a GP who can access relevant diagnostic tests. Although this may be partly improved through improved access to diagnostic tests, there are likely to be additional elements that influence the ways in which potential cancer symptoms are identified and managed within the context of primary care.
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